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INTRODUCTION
Osteoarthritis (OA), the most prevalent
form of skeletal disease, represents a
leading cause of disability after middle
age. This disease is characterized by the
degeneration of joint cartilage in the
knee, hip and hand. Whereas it is ex-
tremely common, the details of its etiol-
ogy and pathogenesis remain unclear.
Recently, a genetic association was re-
ported between the cartilage extracellu-
lar matrix protein asporin (ASPN) and
OA. It was demonstrated that OA sus-
ceptibility is affected by the number of
aspartic acid (D) residues in the amino-
terminal extremity of the asporin protein.
Asporin, also called periodontal
 ligament–associated protein-1 (PLAP-
1), is a new member of the family of
small leucine-rich proteoglycans
(SLRPs) (1–3). The SLRP family, which
composes a major noncollagen compo-
nent of the extracellular matrix, consists
of 13 known members that can be di-
vided into three distinct subfamilies on
the basis of their genomic organization,
amino acid sequence similarity and
structure (1). Asporin belongs to the
group of class I SLRPs that also in-
cludes decorin (DCN) and biglycan
(BGN) (2,3). Unlike other family mem-
bers, asporin lacks a glycosaminoglycan
attachment site and hence is not a
“strict” proteoglycan.
In osteoarthritic cartilage, there is likely
a functional imbalance between cytokines
that promote degradation of the matrix,
such as interleukin (IL)-1β or tumor necro-
sis factor (TNF)-α, and those that favor its
repair, such as transforming growth factor
(TGF)-β. Thus, IL-1β and TNFα induce the
expression of metalloproteases in chondro-
cytes and subsequently the destruction of
the cartilage. Additionally, these cytokines
are able to inhibit proteoglycan and colla-
gen synthesis. On the other hand, TGFβ
may take part in the repair potentiality of
cartilage by stimulating the biosynthesis of
matrix components (collagens and proteo-
glycans). It also inhibits the production of
metalloproteases and enhances the expres-
sion of their tissue inhibitors, the tissue in-
hibitor of metalloproteinase (TIMP). How-
ever, to our knowledge, their effect on
ASPN expression has not been described
until now.
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Recent studies have enlightened inter-
action between ASPN and TGFβ1/bone
morphogenetic protein-2 (BMP-2). ASPN
directly binds to TGFβ1 and inhibits
Smad signaling in chondrocytes (4), lead-
ing to the suppression of TGFβ-mediated
expression of the aggrecan and collagen
type II α1 genes and reduced proteogly-
can accumulation. The effect on TGFβ ac-
tivity was allele specific, with the D14 al-
lele resulting in greater inhibition than
other alleles. Similarly, asporin decreases
BMP-2 activity by interaction with this
factor and subsequently is a negative
regulator of osteoblast differentiation
and mineralization (5). In addition, as-
porin was reported to antagonize the
TGFβ by physical interaction with this
factor. Furthermore, the three isoforms of
TGFβ are able to induce ASPN expres-
sion. However, while it is interesting, no
other reports have been published about
regulation of ASPN  expression.
Therefore, in this study, we examined
ASPN expression in human differenti-
ated or dedifferentiated articular chon-
drocytes and its regulation by the major
factors involved in OA, namely the
proinflammatory cytokines IL-1β and
TNFα, and TGFβ. Among the three TGFβ
isoforms present in mammals, we chose
to study only the effect of TGFβ1. In-
deed, it is the most abundant isoform in
articular cartilage, and its expression is
the most affected during OA process (6).
We also examined the role of Sp1, a tran-
scription factor able to regulate others
members of class I SLRPs.
MATERIALS AND METHODS
Cell Culture
Human articular chondrocytes (HACs)
were prepared from femoral head. All
donors (aged between 50 and 83 years,
with a medium age of 71 years) signed
agreement forms before the surgery, ac-
cording to local legislations. Cells were
isolated and cultured as previously de-
scribed (7). Cartilage samples were cut
into small slices, and chondrocytes were
isolated by sequential digestion by type
XIV protease (Sigma-Aldrich, St. Quentin
Fallavier, France) and then type I collage-
nase (from Clostridium histolyticum; Invit-
rogen, Cergy-Pontoise, France). The cell
suspension was filtered, seeded in plastic
vessels at a density of 4 × 104 cells/cm2
and cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum (FCS; Invitro-
gen), 100 IU/mL penicillin, 100 μg/mL
streptomycin and 0.25 μg/mL Fungi-
zone, in an atmosphere of 5% CO2. Dur-
ing expansion, the medium was changed
twice a week. HACs were used as pri-
mary cultures (no passage) and treated
with human recombinant IL-1β (Sigma-
Aldrich, St. Quentin Fallavier, France),
TNFα or TGFβ1 (R&D Systems, Lille,
France).
For dedifferentiation, confluent cells
were harvested by trypsinization
(0.25% trypsin/1 mmol/L EDTA; Invit-
rogen), counted and seeded again at 4 ×
104 cells/cm2. HACs were used in two
passages, since previous experiments in
the laboratory showed that two passages
are sufficient to induce human chondro-
cyte dedifferentiation (8). For redifferen-
tiation studies, chondrocytes, which had
undergone three passages, were encap-
sulated in alginate beads as previously
described (9). Briefly, the cells were sus-
pended in alginate at the density of 2.5 ×
106 cells/mL and then slowly dropped
into a 100 mmol/L CaCl2 solution. After
instantaneous gelation, the beads were
allowed to polymerize further for a pe-
riod of 10 min in CaCl2 solution. After
three washes in phosphate-buffered
saline (PBS), they were finally placed in
DMEM supplemented with 10% FCS.
After 3 wks, the beads were rinsed with
PBS and dissolved in a solution com-
Figure 1. IL-1β and TNFα induces MMPs and IL-6 and IL-8 expression. Primary cultures of
HACs (P0 [no passage]) were cultured for 6–7 d in DMEM + 10% FCS and then maintained
for 24 h in DMEM + 2% FCS before adding 1 ng/mL IL-1β or TNFα. They were incubated with
these cytokines for the indicated times. IL-6, IL-8, MMP1, MMP3, MMP8 and MMP13 mRNA
were defined by RT-PCR. Histograms represent modulation of mRNA level after normaliza-
tion to GAPDH signal. Values are the mean and SD of triplicate experiments. C, control.
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posed of 55 mmol/L sodium citrate and
25 mmol/L EDTA. The suspension was
incubated at 37°C until the beads were
completely dissolved (approximately 
10 min). Centrifugation of the suspen-
sion at 800g for 10 min allows separation
of the cells from their alginate matrix.
The dedifferentiation and redifferentia-
tion of HACs after passages and culture
in alginate beads were controlled by
analysis of the expression of type I and
II collagen.
RNA Extraction and Real-Time
Reverse Transcription–Polymerase
Chain Reaction
Total RNA from primary HAC cultures
were extracted using Trizol (Invitrogen by
Fisher Bioblock Scientific, Illkirch, France).
After extraction, 1 μg of DNase-I–treated
RNA was reverse transcribed into cDNA
in the presence of oligodT and Moloney
murine leukemia virus reverse transcrip-
tase (Invitrogen). The reaction was carried
out at 37°C for 1 h followed by a further
10-min step at 95°C. Amplification of the
generated cDNA was performed by real-
time PCR in an Applied Biosystems
SDS7000 apparatus with appropriate
primers designed with Primer Express
software. The relative mRNA level was
calculated with the 2–ΔΔCT method.
Protein Extraction and Western Blot
Cells were rinsed and scrapped in ra-
dioimmunoprecipitation assay (RIPA)
lysis buffer supplemented with protease
inhibitors. The extracts (30-μg proteins)
were subjected to fractionation in
sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE), trans-
ferred to polyfluorure de vinylidène
(PVDF) membranes (Amersham Bio-
sciences, Orsay, France) and reacted with
goat antiasporin polyclonal antibody
(ab31303; Abcam, Cambridge, UK). Sub-
sequently, membranes were incubated
with antigoat secondary peroxidase-
 conjugated antibody (Santa Cruz
Biotechnology from tebu-bio). The sig-
nals were revealed with SuperSignal
West Pico Chemiluminescent Substrate
(Pierce Perbio Science, Brébières, France)
and exposed to X-ray film. The mem-
branes were also reacted with anti–β-actin
(Santa Cruz Biotechnology from tebu-
bio) to verify equal loading. Densitomet-
ric analyses were performed with ImageJ
software, and histograms represent the
ratio between ASPN and actin.
Transfection Experiments
Sp1 expression vector (pEVR2-Sp1)
was obtained from Guntram Suske (Insti-
tut fur Molekularbiologie and Tumor-
forschung, Marburg, Germany). ASPN-
luciferase fusion plasmids were
previously described (10). Chondrocytes
were transiently nucleofected as previ-
ously described (11). After overnight
transfection, cells were incubated for 
24 h in DMEM containing 2% FCS.
Luciferase Assay
Cells were washed once with PBS and
harvested in lysis buffer. Luciferase activ-
ity was assayed on total cell extracts (Lu-
ciferase Assay Kit; Promega, Charbon-
nières, France) in a luminometer (Berthold
Centro LB 960; Berthold, Thoiry, France),
and β-galactosidase activity was assayed
by a colorimetric assay. Luciferase activi-
ties were normalized to transfection effi-
ciency, and transcriptional activities were
expressed as relative luciferase units
(mean ± SD of triplicates).
Nuclear Extracts and Electrophoretic
Mobility Shift Assay
Nuclear extracts were prepared as
 described previously (11). For electro -
phoretic mobility shift assay (EMSA), 
5 fentomoles [γ-32P]ATP-labeled probes
and 7 μg of nuclear extracts from chon-
drocytes were incubated at room temper-
ature for 15 min in binding buffer 
(20 mmol/L Tris-HCl, pH 7.5, 1 mmol/L
dithiothreitol, 100 mmol/L NaCl, 5%
bovine serum albumin, 0.1% Nonidet 
Figure 2. ASPN inhibition by IL-1β and TNFα (time-response). Primary cultures of HACs (P0
[no passage]) were cultured for 6–7 d in DMEM + 10% FCS and then maintained for 24 h
in DMEM + 2% FCS before adding 1 ng/mL IL-1β or TNFα. They were incubated with these
cytokines for the indicated times. ASPN mRNA level was defined by RT-PCR. Graphs repre-
sent modulation of ASPN mRNA level after normalization to GAPDH signal. Values are the
mean and SD of triplicate experiments (A). Similar experiments were performed before
protein extraction. Then ASPN protein level was analyzed by Western blot. The amounts of
ASPN protein were quantified by densitometry using ImageJ, normalized against β-actin.
Histograms represent the mean of values relative to control and SD of three experiments
(B). C, control.
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P-40, 10% glycerol, 25 μmol/L ZnCl2)
and 2 μg poly(dI-dC)·(dI-dC). The fol-
lowing probes were used (only the for-
ward strand is shown): AGTTTCCCTG
ACATGCTATAGCAG (probe 1);
AAAAAAAGTATGGTTCTT (probe 2);
CATCTGAAGTTTGGGTATATAC
(probe 3); GTCTATACAGGTTGAGTAAT
TTTT (probe 4); and CTCCGACTGC
ACTTTCAATGGCCAG (probe 5). The
putative Sp1 binding site is underlined.
Samples were resolved on a 7% nonde-
naturating polyacrylamide gel and ex-
posed for autoradiography.
Statistical Analysis
All experiments were repeated at least
3× each with different donors, and simi-
lar results were obtained. Only represen-
tative experiments are shown. Data are
presented as the mean ± SD of triplicate
experiments. Statistical significance was
determined by the Student t test. P val-
ues <0.05 were considered significant
(***P < 0.001; **P < 0.01; *P < 0.05 versus
controls).
RESULTS
Proinflammatory Cytokines
Downregulate Asporin Expression
We treated human articular chondro-
cytes with IL-1β and TNFα. These treat-
ments mimic, in vitro, inflammatory as-
pects observed during OA process; in
particular, they strongly induce expres-
sion of metalloproteinases (MMP1,
MMP3, MMP9 and MMP13) and cy-
tokines (IL-6 and IL-8) (Figure 1).
First, we examined the effect of IL-1β
and TNFα (1 ng/mL) on asporin expres-
sion in human articular chondrocytes
cultured in DMEM + 2% FCS. Using real-
time reverse transcription–polymerase
chain reaction (RT-PCR) (Figure 2A), we
showed that these proinflammatory cy-
tokines significantly reduce asporin
mRNA level. This marked decrease was
seen as early as 3 and 6 h of incubation
with IL-1β and TNFα, respectively, and
was maintained for at least 48 h. At the
protein level, 48 h of treatment with IL-
1β reduced ASPN expression, whereas 24
h of incubation did not induce a signifi-
cant effect. In addition, we were unable
to detect any effect after both 24 and 48 h
of treatment with 1 ng/mL TNFα (Fig-
ure 2B).
Dose-response experiments showed
that 0.1 ng/mL IL-1β for 48 h is suffi-
cient to repress asporin mRNA expres-
sion (70%) (Figure 3A), whereas a
higher concentration (>1 ng/mL) was
required to reduce protein expression
(Figure 3B). Similarly, 0.5 ng/mL TNFα
was sufficient to drop ASPN mRNA ex-
pression, whereas at least a 10-fold
higher concentration was required to in-
duce reduction of ASPN protein expres-
sion (Figure 3).
TGFβ Differentially Modulates Asporin
Expression according to FCS Amounts
We pursued this study by the analysis
of TGFβ1 effect on ASPN (Figure 4). We
treated cells for increased times with 
5 ng/mL TGFβ1 or with increased doses
for 24 h in DMEM + 2% FCS. Surprisingly,
we obtained no significant modulation of
ASPN mRNA level upon TGFβ1 treat-
ment (Figure 4A, B). This is in disagree-
ment with Igekawa’s work, which ob-
served an increase under TGFβ (10). But,
these authors treated cells in 0.2% FCS.
For this reason, we reproduced this exper-
iment with a different concentration of
FCS (0% to 2% to 10%) (Figure 4C). First,
we found that asporin mRNA level de-
creased with the amount of FCS. Second,
as in the preceding figure, TGFβ did not
affect asporin mRNA level when chondro-
cytes were cultured in the presence of FCS
(2% or 10%). However, in FCS-free me-
dium, TGFβ significantly increased as-
porin expression. This induction was also
observed at the protein level (Figure 4D).
Dedifferentiation of HAC Reduces
ASPN Expression
ASPN expression was evaluated at
mRNA levels in chondrocytes that un-
Figure 3. ASPN inhibition by IL-1β and TNFα (dose-response). HACs were incubated with in-
creased dose of IL-1β and TNFα for 48 h. ASPN mRNA level was defined by RT-PCR. Graphs
represent modulation of ASPN mRNA level after normalization to GAPDH signal. Values are
the mean and SD of triplicate experiments (A). Similar experiments were performed be-
fore protein extraction. Then ASPN protein level was analyzed by Western blot. Histograms
represent the mean of values relative to control and SD of three experiments (B). ***P <
0.001; **P < 0.01; *P < 0.05 versus controls.
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derwent up to three passages before in-
clusion in the three-dimensional scaffold
(alginate). These successive passages
lead dedifferentiation of chondrocytes
characterized, among others, by a low
level of collagen type II and aggrecan
and a high expression of collagen type I
and III (Figure 5). On the contrary, algi-
nate culture of chondrocytes passaged
three times restores, at least in part, the
phenotype of chondrocytes with an in-
creased expression of collagen type II
and a reduction of collagen types I and
III (see Figure 5) (8). Clearly, whereas
ASPN expression decreased in a passage-
dependent manner (Figure 6A), it
strongly increased when chondrocytes,
dedifferentiated after three passages,
were cultured for 3 wks in alginate beads
(Figure 6B).
Sp1 Upregulates ASPN Expression
through the –473/–140 Region of the
ASPN Promoter
Sp1 is one of the major transcription
factors controlling chondrocyte metabo-
lism. Indeed, it regulates numerous ma-
trix genes, such as collagen II, decorin
and biglycan (12,13). Because Sp1 is
downregulated during dedifferentiation
of chondrocytes (Figure 7) (14) and up-
regulated by alginate culture (see Fig-
ure 5), we hypothesized that this tran-
scription factor may regulate ASPN
expression. Figure 7A shows that Sp1
ectopic expression increased ASPN ex-
pression in both primary and twice-
 passaged chondrocytes.
Then, we wondered whether Sp1 was
able to bind to the ASPN promoter. First,
transient cotransfection of ASPN pro-
Figure 4. Differential regulation of ASPN expression by TGFβ. HACs were cultured as in Fig-
ure 1. Then, after a 24-h incubation in DMEM + 2% FCS, they were treated with 5 ng/mL
TGFβ for the indicated times (A) or with increased concentration for 24 h (B). HACs were
also incubated in 0, 2 or 10% FCS for 24 h before adding TGFβ (5 ng/mL) for an additional
24-h period (C). ASPN mRNA expression was defined by real-time PCR. HACs were also
treated with TGFβ1 for 24 or 48 h in the absence of serum, and Western blot was per-
formed. Histograms represent the mean of values relative to control and SD of three ex-
periments (D). ***P < 0.001; **P < 0.01; *P < 0.05 versus controls. C, control. 
Figure 5. Passages induce alteration of
HAC phenotype, which is reversed by algi-
nate culture. Human articular chondro-
cytes were passaged twice and subse-
quently maintained in culture for 7 d. At
the end of the incubation, RNA was ex-
tracted and reversed transcribed. Then,
aggrecan, COL2A1, COL1A1, COL1A2 and
COL3A1 mRNA levels were assayed by
real-time PCR (A). P3 (at three passages)
HACs were also cultured 1 or 21 d in algi-
nate beads (B–D,) and collagen mRNA
levels were assayed by real-time PCR (B).
***P < 0.001; **P < 0.01; *P < 0.05 versus
controls. P3, at three passages.
moter and Sp1 expression vector re-
vealed that Sp1 increases the transcrip-
tional activity of a construct driven by
the –473/+14 ASPN promoter in both
primary and passaged chondrocytes. On
the contrary, Sp1 was not able to increase
activity of a shorter construct (–140/+14),
suggesting that Sp1 may act through a
region located between –473 and –140 bp
upstream of the transcription start site
(Figure 7B, C).
Sp1 Is Able to Bind to the –473/–140
Region of the Human ASPN Promoter
Analysis of this ASPN promoter (re-
gion –473/–140) with Patch_Search
(http:// www.gene-regulation.com/cgi-
bin/ pub/programs/patch/bin/ patch.
cgi), TFBind (15) and TRED (http://
rulai.cshl. edu/cgi-bin/TRED/ tred.
cgi?process= searchTFSiteForm) showed
five putative binding sites for Sp1
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 (Figure 8A) in this region. We used
these identified sequences as probes in
EMSA experiments to determine
whether Sp1 is able to bind to the
ASPN promoter. These probes were in-
cubated with nuclear extracts of pri-
mary HACs transfected with pEVR2-
Sp1 or pEVR2. One delayed
protein-DNA complex was observed
with probe 4 (–238/–261) and with a
weaker intensity with probes 1
(–452/–428) and 5 (–142/–166). This
complex was enhanced by ectopic ex-
pression of Sp1 for these three probes
(Figure 8B). No bands were detected
with probes 2 (–356/–339) and 3
(–330/–308) (not shown). Thereafter,
antibody interference assays were per-
formed with antibodies targeting Sp1,
using probe 4. The binding activity of
the complex to probe 4 was decreased
in the presence of the Sp1 antibody, in-
dicating that this complex contains Sp1
(Figure 8C). Therefore, Sp1 is able to
bind to the –473/–140 region of the
human ASPN promoter.
DISCUSSION
Asporin has been reported to be abun-
dantly expressed in OA articular carti-
lage (2). However, few data have been
reported about its regulation. In this
study, we described the regulation of as-
porin expression in human articular
chondrocytes. Our data demonstrate that
asporin expression is regulated by the
major cytokines involved in cartilage ho-
meostasis and OA, namely TGFβ, IL-1β
and TNFα.
First, we tried to mimic the OA pro-
cess in vitro in two different ways. On
one hand, we treated HACs with IL-1β
and TNFα to reproduce the increased
levels of proinflammatory cytokines ob-
served in OA synovial fluid. On the
other hand, we analyzed ASPN expres-
sion in passaged HACs. Indeed, re-
peated passages of chondrocytes mim-
ics some of the alterations of the
chondrocyte phenotype observed dur-
ing OA, at least in the late stages of the
disease (stage of fibrocartilages). Pas-
sages induce morphogenic alterations
of cells, accompanied by profound bio-
chemical changes including the loss of
production of cartilage-specific macro-
molecules, that is, type II collagen in
the profit of type I collagen synthesis
(16). However, this model is not able to
reproduce the other modifications un-
dergone by OA chondrocytes and no-
tably the induction of type × collagen,
specific of hypertrophy stage. There-
after, we used the alginate bead, a cul-
ture system that has been shown to re-
vert to a chondrocytic profile from a
phenotypically altered chondrocytes by
several passages on plastic flasks
(17,18).
We found that proinflammatory cy-
tokines, as well as chondrocyte dedif-
ferentiation, decrease ASPN expression.
This ASPN downregulation was sur-
prising. Indeed, analysis of microarrays
publicly available in Gene Expression
Omnibus (NCBI databases) suggests
that ASPN expression is induced dur-
ing OA (GSE8077) and rheumatoid
arthritis (GDS2952). However, a similar
regulation was reported for other close
small leucine-rich proteoglycans.
Whereas decorin and biglycan concen-
trations are higher in OA cartilage
 (either in human OA [20,21] or in ex-
perimental models [20]), they are
downregulated by IL-1β and passages
(22,23).
On the contrary, ASPN expression is
upregulated by TGFβ1. Similar results
with BMP-2/TGFβ were already re-
cently reported (10,24). However, we
answer questions raised by these re-
ports, since we demonstrate here for
the first time that TGFβ exerts its posi-
tive effect on ASPN only when cells are
cultured in the absence (our data) or
Figure 7. Sp1 upregulates ASPN expression
in chondrocytes. HACs (P0 [no passage] or
P2 [at two passages]) were transfected
with Sp1 expression vector (pEVR2-Sp1) or
with the insertless plasmid (2 μg). After 6 h,
the medium was changed to DMEM + 2%
FCS for 24 h. Total RNA was isolated and
asporin and Sp1 mRNA levels were ana-
lyzed and normalized with GAPDH level.
Values are the mean and SD of triplicate
experiments (A). P0 or P2 HACs were nu-
cleofected with 2 mg pEVR2-Sp1 (or insert-
less pEVR2 vector) and ASPN promoter
constructs. After 24 h, luciferase activities
(relative luciferase units [RLU]) were deter-
mined and expressed as percent of con-
trols (B, C). ***P < 0.001; **P < 0.01; *P < 0.05
versus controls.
Figure 6. ASPN expression according to
differentiation status of chondrocytes.
Human articular chondrocytes, cultured
as described in Materials and Methods,
were passaged up to three times and
subsequently maintained in culture for 
7 d (A–C). P3 HACs were also cultured
1 or 21 d in alginate beads (B–D). At the
end of the incubation, RNA was ex-
tracted and reversed-transcribed. Then,
asporin and Sp1 mRNA level was assayed
by real-time PCR. ***P < 0.001; **P < 0.01;
*P < 0.05 versus controls. P3, at three
 passages.
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with very weak levels of FCS (0.2%
[10]). Further experiments would be re-
quired to understand the mechanism
involved in the differential effect of
TGFβ according to FCS level. However,
a different hypothesis may be pro-
posed. First, several factors contained
in FCS modulate biological effects of
TGFβ. For instance, fibroblast growth
factor (FGF) acts synergically with
TGFβ to inhibit collagen II synthesis in
chondrocytes (25). On the contrary,
other proteins contained in the serum,
such as α2-macroglobuline, are able to
sequestrate TGFβ and block its interac-
tion with its receptors and subse-
quently its effects. Another hypothesis
is ASPN expression may depend on the
proliferation state of chondrocytes. In-
deed, TGFβ1 differentially regulates
type II collagen expression in prolifera-
tive and nonproliferative chondrocytes
(26).
The findings of Kou et al. (10) indi-
cate that TGFβ1 induces ASPN through
the Smad pathway and involves Smad3
in particular. They suggest that ASPN is
the indirect target of Smad3, and hence,
its expression could be influenced by
other mediators, such a GADD45, a fac-
tor that upregulates biglycan upon
TGFβ treatment and is a target gene of
Smad3 (10). In this study, we propose a
role for Sp1, a transcriptional factor
able to regulate decorin and biglycan
expression. Here, we found that Sp1
upregulates ASPN expression and is
able to bind to the ASPN promoter.
Others transcriptional factors, espe-
cially Sox9, Ets and Runx family fac-
tors, may be hypothesized to be impor-
tant in the control of ASPN expression.
Indeed, interestingly, numerous puta-
tive binding sites for Hox/Runx and
Ets/FKHD/Stat are present in the first
intron of ASPN (27). Therefore, because
Smads are known to modulate tran-
scription of Runx and HOX transcrip-
tion factors, whereas IL-1β induces 
Ets family expression, these factors 
may be potential mediators of ASPN
 expression.
In summary, the present work docu-
ments the regulation of ASPN expres-
sion in human articular chondrocytes
and enlightens the crucial influence of
cytokines and cell differentiation status.
However, while we present new knowl-
edge in OA physiopathology, it is diffi-
cult to conciliate our in vitro findings
with data obtained from OA patients.
Nevertheless, it seems that this appar-
ent contradiction between in vitro re-
sults and in vivo observations is general
to class I SLRP and that ASPN is regu-
lated in the same way as decorin and
biglycan.
ACKNOWLEDGMENTS
We thank Dr. Suske (Institut fur
Molekularbiologie and Tumorforschung,
Marburg, Germany) for providing
pEVR2-Sp1 and Thomas Osouf for his
help with the analysis microarray. 
E Duval, N Bigot and M Hervieu re-
ceived fellowships from the Regional
Council of Lower Normandy. This work
was supported in part by the Lions
Clubs from Normandy (France).
DISCLOSURE
The authors declare that they have no
competing interests as defined by Molec-
ular Medicine, or other interests that
might be perceived to influence the re-
sults and discussion reported in this
paper.
Figure 8. Sp1 binds to the ASPN promoter. The region –473/–140 of the human ASPN gene
was analyzed with Patch_Search, TFBind and TRED. The putative Sp1 DNA binding sites are
in bold (A). EMSA reactions were performed using the 5′ end–labeled probes, incubated
with 7 mg of nuclear extract from chondrocytes nucleofected with Sp1 expression vector
(B). Nuclear extracts were also preincubated with IgG or Sp1 antibody before incubation
with probe 4 (C).
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